Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LOPERAMIDE | 2MG | TABLET | Actual shortage | 2017-03-10 | 2017-10-05 | 372 |
| APO-LORATADINE | 10MG | TABLET | Resolved | 2025-01-09 | 2025-04-17 | 247397 |
| APO-LORAZEPAM | 0.5MG | TABLET | Resolved | 2024-04-12 | 2024-04-26 | 225014 |
| APO-LORAZEPAM | 0.5MG | TABLET | Resolved | 2024-06-27 | 2024-09-20 | 231484 |
| APO-LORAZEPAM | 1MG | TABLET | Resolved | 2024-07-12 | 2024-09-20 | 232846 |
| APO-LORAZEPAM | 0.5MG | TABLET | Resolved | 2017-03-10 | 2017-08-08 | 375 |
| APO-LORAZEPAM | 0.5MG | TABLET | Resolved | 2021-06-18 | 2021-09-20 | 141244 |
| APO-LORAZEPAM | 1MG | TABLET | Resolved | 2017-10-23 | 2018-01-22 | 26594 |
| APO-LORAZEPAM | 1MG | TABLET | Resolved | 2018-03-20 | 2018-06-12 | 43511 |
| APO-LORAZEPAM | 2MG | TABLET | Resolved | 2020-08-12 | 2020-10-05 | 122071 |
| APO-LORAZEPAM | 2MG | TABLET | Resolved | 2021-08-03 | 2021-09-07 | 143401 |
| APO-LORAZEPAM | 2MG | TABLET | Resolved | 2021-12-01 | 2021-12-20 | 150252 |
| APO-LORAZEPAM | 2MG | TABLET | Resolved | 2022-04-01 | 2022-05-13 | 157698 |
| APO-LOSARTAN | 50MG | TABLET | Resolved | 2017-03-12 | 2017-03-16 | 722 |
| APO-LOSARTAN | 50MG | TABLET | Actual shortage | 2018-05-01 | 2019-03-15 | 47652 |
| APO-LOSARTAN | 100MG | TABLET | Actual shortage | 2018-05-15 | 2019-04-11 | 49490 |
| APO-LOSARTAN | 25MG | TABLET | Actual shortage | 2018-07-11 | 2019-03-15 | 55284 |
| APO-LOSARTAN | 100MG | TABLET | Actual shortage | 2018-12-27 | 2019-04-17 | 70523 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Resolved | 2017-10-24 | 2018-09-11 | 26827 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Resolved | 2018-02-13 | 2018-09-10 | 39656 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |